...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oral oncology >Controversies in the systemic treatment of Nasopharyngeal carcinoma
【24h】

Controversies in the systemic treatment of Nasopharyngeal carcinoma

机译：鼻咽癌全身治疗中的争议

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In conjunction with radiotherapy, the concurrent use of systemic chemotherapy has been proven to improve treatment outcome and thus have been incorporated into the treatment paradigm for patients with loco-regionally advanced Nasopharyngeal carcinoma. The benefits from the use of chemotherapy in stage II disease remain controversial. There is now also increasing evidence for the use of neoadjuvant chemotherapy prior to definitive concurrent chemoirradiation, which is associated with decreased risks of distant metastases, translating to improvement in overall survival. Dose intensity of chemotherapy administered during radiotherapy has been shown to have prognostic significance in NPC treatment. The role of adjuvant chemotherapy after completion of concurrent chemoirradiation is less well defined, with studies indicating an insignificant survival improvement. However, this approach may still be of value in patients with high-risk disease. Data in support of this approach shall become available in the coming years. This article will discuss and highlight these findings and controversies in systemic treatment of NPC.
机译：与放疗相结合，已证明同时使用全身化学疗法可改善治疗效果，因此已被纳入局部局部晚期鼻咽癌患者的治疗范例中。在II期疾病中使用化学疗法的益处仍存在争议。现在也有越来越多的证据表明，在确定的同步放化疗之前使用新辅助化疗，这与降低远处转移的风险有关，从而改善了总生存期。放疗期间化疗的剂量强度已显示对NPC治疗具有预后意义。并发化学放疗完成后辅助化疗的作用尚不清楚，研究表明存活率的改善不明显。但是，这种方法在高危疾病患者中仍然可能有价值。支持这种方法的数据将在未来几年中获得。本文将讨论并重点介绍在鼻咽癌全身治疗中的这些发现和争议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号